ATE412763T1 - Antikörper-abhängige vergrösserung der alphavirus-infektvität - Google Patents

Antikörper-abhängige vergrösserung der alphavirus-infektvität

Info

Publication number
ATE412763T1
ATE412763T1 AT00963282T AT00963282T ATE412763T1 AT E412763 T1 ATE412763 T1 AT E412763T1 AT 00963282 T AT00963282 T AT 00963282T AT 00963282 T AT00963282 T AT 00963282T AT E412763 T1 ATE412763 T1 AT E412763T1
Authority
AT
Austria
Prior art keywords
cell
alphavirus
subject
preferred
infectivity
Prior art date
Application number
AT00963282T
Other languages
English (en)
Inventor
Gene Macdonald
Robert Johnston
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE412763T1 publication Critical patent/ATE412763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00963282T 1999-08-31 2000-08-30 Antikörper-abhängige vergrösserung der alphavirus-infektvität ATE412763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15171899P 1999-08-31 1999-08-31
US17743500P 2000-01-21 2000-01-21

Publications (1)

Publication Number Publication Date
ATE412763T1 true ATE412763T1 (de) 2008-11-15

Family

ID=26848900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00963282T ATE412763T1 (de) 1999-08-31 2000-08-30 Antikörper-abhängige vergrösserung der alphavirus-infektvität

Country Status (8)

Country Link
US (1) US7651998B1 (de)
EP (1) EP1208217B1 (de)
JP (1) JP2003508056A (de)
AT (1) ATE412763T1 (de)
AU (1) AU782645B2 (de)
CA (1) CA2383519A1 (de)
DE (1) DE60040672D1 (de)
WO (1) WO2001016343A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
US7045335B2 (en) 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US7419674B2 (en) 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
CA2572921C (en) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
CA2597921A1 (en) 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
EP2164511A1 (de) * 2007-05-22 2010-03-24 Baylor College Of Medicine Immunkomplex-impfung als strategie zur verstärkung der immunität von älteren menschen und anderen immumgeschwächten personen
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US8828961B2 (en) 2010-10-27 2014-09-09 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0659885A1 (de) 1993-12-21 1995-06-28 Akzo Nobel N.V. Impstoffe gegen von Antikörper abhängende Vergrösserung (ADE) der Virus-Infektivität
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
JP2002512003A (ja) * 1997-11-14 2002-04-23 コノート ラボラトリーズ リミテッド パラミキソウイルスワクチンのためのアルファウイルスベクター
US20010041876A1 (en) 1999-12-23 2001-11-15 Creagan Christopher Cosgrove Superabsorbent and nonwoven composites for personal care products

Also Published As

Publication number Publication date
US7651998B1 (en) 2010-01-26
WO2001016343A1 (en) 2001-03-08
JP2003508056A (ja) 2003-03-04
CA2383519A1 (en) 2001-03-08
AU7471800A (en) 2001-03-26
EP1208217A1 (de) 2002-05-29
AU782645B2 (en) 2005-08-18
EP1208217B1 (de) 2008-10-29
DE60040672D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
Zom et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates
Schuler Dendritic cells in cancer immunotherapy
Huang et al. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
GB2431582A (en) Dendritic cell vaccines for treating cancer made from embryonic stem cells
MX2019000149A (es) Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
Li et al. Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non‐targeted tumour epitopes
EP1633784A4 (de) Ovr110-antikörperzusammensetzungen und anwendungsverfahren
NO20021992D0 (no) Anti-prostatastamcelleantigen(PSCA)-antistoffpreparat og fremgangsmåter for anvendelse
ATE432085T1 (de) Stimulationsfaktor für dendriten
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
ATE412763T1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
DK1516881T3 (da) Sammensætning og fremgangsmåde til modulering af dendritcelle-T-celle-interaktioner
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
PL338478A1 (en) Immunological response in respect to hpv antigens induced by compositions comprising a hpv antigen and a shock protein or expression vector capable to express such protein
Anticoli et al. Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
Wu et al. A novel vaccine targeting glypican-3 as a treatment for hepatocellular carcinoma
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
WO2006053110A3 (en) Ovr110 antibody compositions and methods of use
DK1093465T3 (da) Fremgangsmåde til frembringelse eller forögelse af en T-cellerespons mod en målcelle ved brug af kompleks omfattende et HLA klasse I molekyle og et tilkoblingsorgan
Bao et al. Chimeric exosomes functionalized with sting activation for personalized glioblastoma immunotherapy
DE50008756D1 (de) Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
BR0015597A (pt) Uso de anticorpos como vacinas
ES2234287T3 (es) Vacunas que comprenden proteinas de choque termico (hsp) inducidas por citoquinas.
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties